Understanding this is more important than ever in psychedelic research because scientists think DMT may be an endogenous neurotransmitter.
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
The primary active compound in this plant is more potent than LSD.
“In the pharmaceutical drug development community, this is what you dream about.”
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
Although aeruginascin is only present in psilocybin mushrooms and bufotenidine is present in toads, their structural and chemical similarities may be surprising.
This is the second crystal structure of this compound, providing additional options for developing psychedelics into therapeutic drug formulations.
Baeocystin does not cause the head twitch in mice, but its metabolite norpsilocin is more potent than psilocin.